Gender differences in cancer patients with acute venous thromboembolism.

The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). During the course of anticoagulation, cancer women with VTE had a better outcome than men.

Martín-Martos F ，Trujillo-Santos J ，Barrón M ，Vela J ，Javier Marchena P ，Braester A ，Hij A ，Hernández-Blasco L ，Verhamme P ，Manuel M ，RIETE Investigators ... -  《-》

Gender differences in patients with venous thromboembolism and five common sites of cancer.

The outcome of cancer patients with venous thromboembolism (VTE) may differ according to gender. We used the RIETE database to compare the rate of VTE recurrences, major bleeding and mortality in patients with lung, colorectal, pancreatic, hematologic or gastric cancer during the course of anticoagulation, according to gender. As of January 2016, 11,055 patients with active cancer were enrolled: 1,727 had lung cancer, 1,592 colorectal, 840 hematologic, 517 pancreatic and 459 had gastric cancer. Compared with men (N = 3,130), women (N = 2,005) were more likely to have colorectal, pancreatic or hematologic cancer, and less likely to have lung cancer. Most patients (91%) were initially treated with low-molecular-weight heparin (LMWH), but women received higher daily doses per body weight. Then, 66% kept receiving LMWH for long-term therapy. During the course of anticoagulation, 302 patients developed recurrent VTE, 220 bled and 1,749 died. Compared with men, women had a similar rate of VTE recurrences or major bleeding, and a lower mortality (risk ratio [RR]: 0.90; 95% CI: 0.82-0.99). When separately comparing outcomes according to cancer site, women with lung cancer had a lower mortality (RR: 0.79; 95% CI: 0.70-0.92), those with colorectal cancer had a higher mortality (RR: 1.25; 95% CI: 1.02-1.54) and those with gastric cancer had a higher rate of VTE recurrences than men (RR: 2.47; 95% CI: 1.04-5.89). VTE women with lung, colorectal, pancreatic, haematological or gastric cancer experienced a similar outcome during the course of anticoagulant therapy than men with similar cancers.

Martín-Martos F ，Trujillo-Santos J ，Del Toro J ，Bura-Riviere A ，Lorenzo A ，Barillari G ，Soler S ，Mahè I ，Sahuquillo JC ，Monreal M ，RIETE Investigators ... -  《-》

Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.

Blanco-Molina A ，Enea I ，Gadelha T ，Tufano A ，Bura-Riviere A ，Di Micco P ，Bounameaux H ，González J ，Villalta J ，Monreal M ，RIETE Investigators ... -  《-》

Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.

Lecumberri R ，Alfonso A ，Jiménez D ，Fernández Capitán C ，Prandoni P ，Wells PS ，Vidal G ，Barillari G ，Monreal M ，RIETE investigators ... -  《-》

Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia.

In patients with venous thromboembolism (VTE) and factor V Leiden (FVL) or prothrombin 20210G-A mutation (PTM), the influence of gender on outcome has not been consistently studied. We used the RIETE (Registro Informatizado Enfermedad TromboEmbolica) database to assess the existence of gender differences in the rate of VTE recurrences (deep vein thrombosis [DVT] or pulmonary embolism [PE]) or major bleeding during the course of anticoagulation and after its discontinuation in FVL and PTM carriers. From March 2001 to September 2016, 11,224 VTE patients underwent thrombophilia testing. Of these, 1,563 were FVL carriers (863 men and 700 women) and 1,231 were PTM carriers (659 men and 572 women). During the course of anticoagulant therapy, men with FVL had a 6-fold higher rate of VTE recurrences than major bleeds (31 vs. 5 events). In women with FVL, the rate of VTE recurrences was 2-fold higher (16 vs. 8), as was in men (17 vs. 8) or women (17 vs. 9) with PTM. After discontinuing anticoagulation, men with FVL had a 3-fold higher rate of DVT recurrences than women (hazard ratio [HR]: 3.13; 95% CI: 1.79-5.67), with no differences in PE recurrences. Among patients with PTM, there were no gender differences in the rate of DVT (HR: 1.89; 95% CI: 1.00-3.65) or PE recurrences (HR: 1.82; 95% CI: 0.83-4.12). During the anticoagulation course, men with FVL are at a much higher risk for VTE recurrences than bleeding. After discontinuing anticoagulation, men with FVL are at an increased risk for DVT recurrences.

Tzoran I ，Papadakis E ，Brenner B ，Valle R ，López-Jiménez L ，García-Bragado F ，Riera-Mestre A ，Villalobos A ，Quintavalla R ，Monreal M ，RIETE Investigators ... -  《-》